

**DRUG PRIOR AUTHORIZATION COMMITTEE**

**December 19, 2019**

AGENDA

MO Coalition for Community Behavioral Healthcare  
Lower Level CEO Room,  
221 Metro Drive, Jefferson City, MO

10:00 - 10:05	Welcome, Announcements and Introductions	Chairperson
10:05 - 10:15	Minutes Review	Discussion/Approval
10:15 - 10:25	Pharmacy Program/ Budget Update	Elizabeth Short
10:25 - 10:35	DUR Update	Mark Roaseau

**Old Business**

10:35 – 10:45	<b>A. Implementation Schedule (Criteria for Previously Approved Clinical Edits, Step Therapies and PA's)</b> <ul style="list-style-type: none"><li>• <b>Multiple Sclerosis (MS) Agents</b></li></ul>	Josh Moore/ Mark Roaseau
---------------	--	-----------------------------

**New Business**

10:45 – 11:00	<b>B. Proposed Actions - New Drug/Product Review</b> (See website and Attached Summary) <ul style="list-style-type: none"><li>i. Open Access</li><li>ii. Clinical Edit/Step Therapy</li><li>iii. PDL Products</li><li>iv. Prior Authorization</li></ul>	Josh Moore/ Mark Roaseau
---------------	--	-----------------------------

11:00 – 11:45	<b>C. Clinical Edits</b> <ul style="list-style-type: none"><li><b>I. 15 Day Supply – Oral Oncology Fiscal Edit</b></li><li><b>II. 15 Day Supply Fiscal Edit</b></li><li><b>III. Acetaminophen Cumulative Dose Clinical Edit</b></li><li><b>IV. Biosimilar Fiscal Edit</b></li><li><b>V. Corlanor Clinical Edit</b></li><li><b>VI. Cystic Fibrosis Clinical Edit</b></li><li><b>VII. Diabetic Supply Quantity Limit Fiscal Edit</b></li><li><b>VIII. Entresto Clinical Edit</b></li><li><b>IX. High Cost Medication Kits Fiscal Edit</b></li><li><b>X. MME Accumulation Clinical Edit</b></li><li><b>XI. Non-Oral Contraceptive Clinical Fiscal Edit</b></li><li><b>XII. PrEP Fiscal Edit</b></li><li><b>XIII. Short-Acting Opioid Combinations Clinical Edit</b></li><li><b>XIV. Short-Acting Opioid Single Agents Clinical Edit</b></li><li><b>XV. TIRF Clinical Edit</b></li><li><b>XVI. Typical Antipsychotic Clinical Edit</b></li></ul>	
---------------	--	--

## **XVII. Zulresso Clinical Edit**

### **11:45 – 1:00 D. Preferred Drug List (PDL)**

Discussion, Public Hearing and Decision will be held for each edit

- I. Alzheimer's Agents**
- II. Antiandrogenic Agents PDL Edit**
- III. Antiemetic Agents: 5-HT3, NK1 & Other Agents**
- IV. Antiemetic Agents: THC Derivatives**
- V. Anti-Migraine Agents: Serotonin (5-HT1) Receptor Agonists**
- VI. Anti-Parkinsonism: MAO-B Inhibitor Agents**
- VII. Anti-Parkinsonism: Non-Ergot Dopamine Agonists**
- VIII. Calcitonin Gene-Related Peptide (CGRP) Inhibitors**
- IX. Cox-II Inhibitor Agents**
- X. Fibromyalgia**
- XI. GI Motility Agents**
- XII. Glucagon Products**
- XIII. Hereditary Angioedema Agents**
- XIV. Long-Acting Opioid Agents**
- XV. Neuropathic Pain Agents**
- XVI. NSAIDs**
- XVII. Opiate Dependence Agents**
- XVIII. Opiate Emergency Reversal Agents**
- XIX. Respiratory Monoclonal Antibodies (RMA)**
- XX. Sedative Hypnotic Agents**
- XXI. Skeletal Muscle Relaxants**
- XXII. Tramadol-Like Agents**

### **11:45 – 12:45 E. Reference Drug List**

Discussion, Public Hearing and Decision will be held for each edit

- I. Atypical Antipsychotics – Reference List**
- II. Antiretrovirals, Treatment– Reference List**

**F. Preferred Drug List Classes for Dec/Jan**

- i. Process Discussion
- ii. Therapeutic classes/to be announced at meeting

1:00

**LUNCH**

1:15-1:30

**Program Utilization Information - Conduent Update**

Olivia Rush

1:30-1:50

**Other Business**

- *“Top 25” Drugs by Cost/Claims*
- *Clinical Edit Summary Report*
- *Call Center Statistics*

*Informal comments will be accepted from members of the audience at various points in the agenda. Times noted are approximate, Agenda may move more quickly*

**NEXT MEETING: March 19, 2020**

MO Coalition for Community Behavioral Healthcare  
Lower Level CEO Room,  
221 Metro Drive, Jefferson City, MO